Credit Suisse Downgrades Arista Networks to Neutral, Lowers Price Target to $110
Credit Suisse analyst Sami Badri downgrades Arista Networks (NYSE:ANET) from Outperform to Neutral and lowers the price target from $185 to $110.
HC Wainwright & Co. Downgrades Applied Genetic Techs to Neutral
HC Wainwright & Co. analyst Joseph Pantginis downgrades Applied Genetic Techs (NASDAQ:AGTC) from Buy to Neutral.
SVB Leerink Downgrades Myovant Sciences to Market Perform, Raises Price Target to $27
SVB Leerink analyst Roanna Ruiz downgrades Myovant Sciences (NYSE:MYOV) from Outperform to Market Perform and raises the price target from $23 to $27.
Needham Downgrades Tricida to Hold
Needham analyst Serge Belanger downgrades Tricida (NASDAQ:TCDA) from Buy to Hold.
Wedbush Downgrades Applied Genetic Techs to Neutral
Wedbush analyst David Nierengarten downgrades Applied Genetic Techs (NASDAQ:AGTC) from Outperform to Neutral.
Stifel Downgrades Applied Genetic Techs to Hold, Lowers Price Target to $0.34
Stifel analyst Dae Gon Ha downgrades Applied Genetic Techs (NASDAQ:AGTC) from Buy to Hold and lowers the price target from $3 to $0.34.
Cowen & Co. Downgrades PhaseBio Pharmaceuticals to Market Perform
Cowen & Co. analyst Phil Nadeau downgrades PhaseBio Pharmaceuticals (NASDAQ:PHAS) from Outperform to Market Perform.
Cowen & Co. Downgrades Tricida to Market Perform
Cowen & Co. analyst Phil Nadeau downgrades Tricida (NASDAQ:TCDA) from Outperform to Market Perform.
Baird Downgrades Myovant Sciences to Neutral, Raises Price Target to $27
Baird analyst Brian Skorney downgrades Myovant Sciences (NYSE:MYOV) from Outperform to Neutral and raises the price target from $20 to $27.
Canaccord Genuity Downgrades Corus Entertainment to Speculative Buy
Canaccord Genuity analyst Aravinda Galappatthige downgrades Corus Entertainment (TSX:CJR) from Buy to Speculative Buy.